JULY 30, 2017
Orchidia recently achieved unprecedented growth rates in its total sales, where the successful growth rate reached 174% in its first semester with a total sales of 137 million EGP.
Orchidia has regained its second ranking in the midst of the general ranking of companies competing in the ophthalmic pharmaceutical market.
With a market share approaching a quarter (24.3%), thanks to the acquired lead in growth rates among companies operating in the ophthalmological market, where the growth rate was due to 166% increased sales to pharmacies, while the closest competitor achieved 40% growth rate during the first semester of the year.
It is also worth mentioning that the company has acquired the lead of top sales in the tender market for ophthalmology. Orchidia strives to acquire the first rank among ophthalmology pharmaceutical companies in Egypt, during the next two years.
